MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 90 filers reported holding MARINUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $280,631 | -25.6% | 34,861 | +0.3% | 0.01% | -15.4% |
Q2 2023 | $377,396 | +57.4% | 34,751 | 0.0% | 0.01% | +30.0% |
Q1 2023 | $239,782 | +74.0% | 34,751 | +0.4% | 0.01% | +66.7% |
Q4 2022 | $137,823 | -40.1% | 34,629 | 0.0% | 0.01% | -50.0% |
Q3 2022 | $230,000 | +40.2% | 34,629 | +2.2% | 0.01% | +50.0% |
Q2 2022 | $164,000 | -46.4% | 33,879 | +3.4% | 0.01% | -50.0% |
Q1 2022 | $306,000 | +0.3% | 32,765 | +27.6% | 0.02% | +14.3% |
Q4 2021 | $305,000 | -7.9% | 25,680 | -11.8% | 0.01% | 0.0% |
Q3 2021 | $331,000 | -30.2% | 29,128 | +10.2% | 0.01% | -33.3% |
Q2 2021 | $474,000 | +28.5% | 26,431 | +10.9% | 0.02% | +16.7% |
Q1 2021 | $369,000 | +147.7% | 23,825 | +94.5% | 0.02% | +125.0% |
Q4 2020 | $149,000 | +2.8% | 12,250 | +8.9% | 0.01% | -11.1% |
Q3 2020 | $145,000 | – | 11,250 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |